Build a robust medical device security strategy for FDA 510(k)

Roughly one in three 510(k) submissions hits a Refuse to Accept hold before a single substantive review even begins, and cybersecurity deficiencies rank among the most cited reasons. With an average review timeline already stretching to 146 to 147 days in 2025, a preventable security documentation gap can push your launch back by months and burn through capital you cannot afford to lose. This guide breaks down exactly what the FDA expects from a cybersecurity standpoint, how to build security into your device from the start, and the practical steps Indian and US founders need to take to reach clearance without unnecessary detours.

Table of Contents

• Why cybersecurity is now non-negotiable in FDA 510(k) submissions
• Critical cybersecurity documentation: What the FDA expects
• Building a device security strategy that satisfies the FDA
• Startups vs. historical trends: Why the stakes are higher in 2026
• What most founders get wrong about medical device security
• Accelerate FDA-ready device security with expert support
• Frequently asked questions

Key Takeaways

Why cybersecurity is now non-negotiable in FDA 510(k) submissions

The FDA’s posture on cybersecurity has shifted from gentle guidance to hard enforcement. Before 2023, reviewers might flag a missing threat model as a minor deficiency. Today, the same gap can freeze your entire submission. If your device qualifies as a “cyber device,” you are legally required to meet a specific set of security documentation standards before the FDA will even begin substantive review.

FDA premarket cybersecurity guidance requires specific cybersecurity documentation in 510(k) submissions for all devices with cybersecurity risks, including cyber devices under Section 524B of the FD&C Act. This is not optional language buried in a footnote. It is a statutory requirement that took effect with the Consolidated Appropriations Act of 2023.

So what exactly is a cyber device? The FDA’s definition is precise:

A cyber device is one that includes software validated by the sponsor, has the ability to connect to the internet, and contains features or functions that could be vulnerable to cybersecurity threats.

Cyber devices are defined as devices that include software validated by the sponsor, can connect to the internet, and have characteristics vulnerable to cybersecurity threats. That definition covers a surprisingly wide range of products: wearable cardiac monitors, connected glucose meters, hospital infusion pumps with remote dosing features, and even diagnostic imaging software with cloud upload capability.

Two dangerous misconceptions still circulate in startup circles:

• “We can bolt on security at the end.” Security retrofitted after development is almost always incomplete and nearly impossible to document in the way the FDA requires. Threat models built after the fact lack the design-stage evidence reviewers look for.
• “This only applies to big, enterprise-grade devices.” A Bluetooth-enabled pulse oximeter built by a three-person team in Bengaluru or Austin is just as subject to Section 524B as a device from a Fortune 500 medtech company.

Founders who learn this lesson late often discover it when they receive an RTA hold letter, at which point they face a complete documentation rebuild under time pressure. Understanding FDA cybersecurity requirements before you start building is the single highest-leverage move you can make early in development.

Critical cybersecurity documentation: What the FDA expects

Now that we know security is essential, let’s break down what documentation you need to deliver and avoid getting stuck in review holds.

The FDA does not leave you guessing about what to submit. The eSTAR (Electronic Submission Template and Resource) format includes a dedicated cybersecurity section, and reviewers use a structured checklist to evaluate it. Missing or thin documentation in this section is a primary trigger for Additional Information requests. Missing cybersecurity docs can lead to AI requests in roughly 67% of affected cases, which adds weeks or months to your timeline.

Here is a comparison of what pre-2025 submissions often included versus what the FDA now expects:

The FDA premarket cybersecurity guidance is explicit: every submission for a cyber device must include documented evidence of security controls, not just assertions that controls exist.

To build a complete cybersecurity documentation packet, follow these steps:

1. Classify your device. Determine whether it meets the cyber device definition under Section 524B. If it connects to any network, has embedded software, or receives remote updates, assume it qualifies.
2. Conduct a formal threat model. Use a recognized methodology such as STRIDE or PASTA. Map threats to specific device components and data flows.
3. Develop your SBDF and SPDF. The Software Bill of Materials and Design File and the Software Planned Design File must document every software component, including third-party libraries and open-source dependencies.
4. Perform a structured risk assessment. Tie each identified threat to a likelihood and impact rating. Document your mitigations and residual risk acceptance.
5. Run and document security testing. This includes penetration testing for compliance as well as static and dynamic code analysis. Attach test reports with findings and remediation evidence.
6. Map everything to your QMSR. Show how your Quality Management System controls support each cybersecurity requirement.
7. Populate the eSTAR cybersecurity section. Use the template fields exactly as structured. Reviewers flag submissions that dump documents without mapping them to the required fields.

Following these compliance steps systematically is far less painful than trying to reconstruct documentation after an RTA hold.

Building a device security strategy that satisfies the FDA

Once documentation needs are clear, let’s make sure your security strategy is robust from day one with actionable steps.

The most expensive security mistake a startup can make is treating cybersecurity as a documentation exercise rather than an engineering discipline. Founders who integrate security into their development process from the first sprint consistently produce better submissions and face fewer review holds. The reason is simple: FDA reviewers can tell the difference between a threat model that shaped design decisions and one that was reverse-engineered from a finished product.

Early SBDF/SPDF integration and gap analysis against 2025 FDA guidance are the two highest-impact early investments for startups in both India and the US. A gap analysis compares your current security posture against the specific requirements in the FDA’s latest cybersecurity guidance and the eSTAR template. It tells you exactly where you are exposed before a reviewer does.

Core activities your engineering team should build into every development cycle:

• Risk assessment at design kickoff. Before writing a line of code, identify the assets your device protects (patient data, dosing commands, firmware integrity) and the threats most likely to target them.
• Secure design principles. Apply least privilege, defense in depth, and secure boot where applicable. Document every design decision that has a security rationale.
• Threat modeling sprints. Run a structured threat modeling session at each major architecture milestone, not just once at the beginning.
• Validation testing with security scope. Your verification and validation plan must include security test cases. A security risk assessment should feed directly into your V&V protocol.
• Patch and update management plan. The FDA expects you to describe how you will handle post-market security vulnerabilities. Build this into your SPDF from the start.
• Third-party component inventory. Every open-source library and vendor SDK in your stack needs to be tracked in your SBDF. Untracked components are a common gap that triggers reviewer questions.

Pro Tip: The single most common gap we see in startup submissions is a threat model that covers the device in isolation but ignores the broader ecosystem: the mobile app, the cloud backend, the clinical workflow. FDA reviewers evaluate the full attack surface. Make sure your threat model does too. A good penetration testing guide can help you scope this correctly before testing begins.

Fixing security gaps early in development costs a fraction of what it costs to fix them after a submission hold. One startup we worked with spent three months rebuilding their threat model after an RTA. The same work done at the design stage would have taken three weeks.

Startups vs. historical trends: Why the stakes are higher in 2026

After developing a sound security strategy, it’s key to understand how the regulatory and compliance environment has evolved and why startups must avoid old patterns.

The historical data on cybersecurity disclosure in 510(k) submissions is striking. Only 2.13% of software-containing devices submitted between 2002 and 2016 mentioned cybersecurity in their summaries, rising to just 5.5% in 2015 to 2016. That means the overwhelming majority of connected medical devices reached the market with essentially no documented security posture.

Post-2023 enforcement has risen sharply with QMSR and ISO 13485 alignment now embedded in FDA expectations. The agency is not simply asking for more paperwork. It is requiring evidence that security is a core engineering discipline within your quality management system.

“The FDA’s shift from voluntary guidance to statutory enforcement represents the most significant change in 510(k) requirements in a generation. Startups that treat this as a paperwork update rather than a fundamental change in how devices must be built will face repeated submission failures.”

Why does this matter beyond the submission itself? Because the FDA now evaluates your ability to support the device post-market. A weak security posture at submission signals to reviewers that your organization lacks the processes to respond to vulnerabilities discovered after clearance. That concern can delay or derail approval even when your clinical evidence is strong.

Startups that want to avoid common cybersecurity mistakes need to understand that the old playbook of submitting minimal documentation and responding to deficiencies reactively no longer works. The FDA has the statutory authority to refuse submissions outright, and it is using it.

What most founders get wrong about medical device security

Here is an uncomfortable truth from working with dozens of device startups: most founders know security matters, but they consistently underestimate how much evidence the FDA wants to see that security shaped the product, not just the submission.

The pattern repeats itself. A team builds a genuinely innovative device, runs a tight development schedule, and then allocates the final four to six weeks before submission to “handle the cybersecurity documentation.” What follows is a frantic effort to produce a threat model, risk assessment, and test reports that look credible but were never connected to actual design decisions. Reviewers are experienced enough to spot this. The documents may be technically complete but internally inconsistent, and that inconsistency triggers an AI request.

The deeper problem is that many founders treat FDA cybersecurity requirements as a compliance tax rather than a quality signal. The FDA’s requirements exist because insecure medical devices cause real patient harm. A compromised insulin pump or a manipulated cardiac monitor is not a data breach. It is a clinical event. When you internalize that framing, the documentation requirements stop feeling arbitrary and start feeling proportionate.

What separates timely approvals from costly delays is almost always the same thing: teams that integrated real-world compliance steps into their engineering sprints versus teams that tried to produce compliance artifacts after the fact. The former group submits with confidence. The latter group submits and waits for the hold letter.

Pro Tip: Assign a cybersecurity owner within your engineering team at the start of the project, not the start of the submission process. This person owns the threat model, tracks SBDF updates as dependencies change, and ensures every sprint review includes a security checkpoint. This single structural decision prevents the majority of documentation gaps we see in startup submissions.

Accelerate FDA-ready device security with expert support

Getting your 510(k) cybersecurity documentation right the first time requires more than good intentions. It requires structured testing, documented evidence, and a team that understands what FDA reviewers actually look for.

Testvox specializes in exactly this kind of work. Our security testing service is built for medical device startups navigating FDA submission requirements, covering threat modeling support, VAPT aligned with OWASP standards, and test report documentation formatted for regulatory review. We have helped device teams produce submission-ready security packages that hold up under FDA scrutiny. If you want to see what this looks like in practice, our security compliance case study walks through a real patient monitoring device we helped clear. Start your submission on solid ground.

Frequently asked questions

What cybersecurity documents are mandatory for FDA 510(k) submissions?

FDA premarket cybersecurity guidance requires threat modeling, SBDF/SPDF, risk analysis, security test reports, and a completed cybersecurity section within the eSTAR template for all cyber devices.

How long does the FDA take to review 510(k) submissions with cybersecurity risks?

Average review time runs about 146 to 147 days, but missing cybersecurity documentation can trigger an Additional Information request that pauses the clock entirely and extends your timeline by months.

What is a “cyber device” under FDA rules?

A cyber device includes validated software, internet connectivity, and features susceptible to cybersecurity threats, covering most modern connected medical devices regardless of their size or complexity.

What happens if my submission lacks sufficient cybersecurity information?

Your 510(k) can be placed on RTA hold or receive an AI request, and missing cybersecurity docs trigger these outcomes in roughly 67% of affected submissions, causing significant approval delays.

Do small startups in India face different requirements than US companies?

FDA expectations are identical for all submissions regardless of where the company is based. Both Indian and US startups must meet the same QMSR alignment and cybersecurity documentation standards that apply to any 510(k) submission for a cyber device.

Recommended

• Medical device security risk assessment for stronger compliance
• FDA cybersecurity requirements: what startups must know
• Medical device cybersecurity: compliance steps to enter the market
• VAPT Archives – Testvox
• Manufacturer’s Layered Security Approach | Re-Solution Experts